

# Evoq Remedies Limited

CIN: L24230GJ2010PLC059692

**Regd. Office:** A-1106, Empire Business Hub Near AUDA Water Tank,  
Science City Road, Sola Ahmedabad, Gujarat, India – 380060

**E-mail:** [evoqremedies@gmail.com](mailto:evoqremedies@gmail.com) **Website:** [www.evoqremedies.com](http://www.evoqremedies.com)

**Date:** 10<sup>th</sup> April, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400 001.

Dear Sir/ Ma'am,

**Subject: Outcome of Board Meeting held today i.e. Thursday, 10<sup>th</sup> April, 2025**

**Ref: Security Id: EVOQ / Code: 543500**

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held on today, i.e. Thursday, 10<sup>th</sup> April, 2025 at the Registered Office of the Company, situated at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola Ahmedabad – 380 060 which commenced at 3:00 P.M and concluded at 8:00 P.M. has considered and approved:

1. Issuance of Equity Shares through preferential issue for consideration other than cash i.e., swap of Equity Shares for acquisition of upto 51.00% of paid-up equity shares of M/s. Poshan Nutriwell Private Limited ("PNPL").
2. Raising of funds upto Rs. 99.00 Crores (Rupees Ninety-Nine Crores Only) by way of issue of Warrants (hereinafter referred to as "**Convertible Warrants**"), through preferential allotment to the person(s)/ entity(ies) belonging to "Non-Promoter Category", as per Chapter V of SEBI (ICDR) Regulations, 2018, subject to approval of Shareholders and other authorities concerned.
3. Calling of Board Meeting on Friday, 18<sup>th</sup> April, 2025 at 03:00 P.M., at the registered office of the Company for considering the matters in relation to:
  - Issuance of Equity shares other than cash through swap of shares (agenda no. 1);
  - Issuance of Convertible warrants through preferential issue (agenda no. 2); and
  - Calling of Extra-Ordinary General Meeting of the Company.
4. Audited Financial Results for the Half Year and Year ended on 31<sup>st</sup> March, 2025 along with Auditor's Report.

Further, pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, we hereby inform you that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed from Thursday, 10<sup>th</sup> April, 2025 till 48 hours after the conclusion of the meeting.

Kindly take the same on your record and oblige us.

Thanking You.

**For, Evoq Remedies Limited**

**Bhumishth Patel**  
**Managing Director**  
**DIN: 02516641**

|   |
|---|
| <b>EVOQ REMEDIES LIMITED</b>                                    |
| <b>CIN:L24230GJ2010PLC059692</b>                                |
| <b>A-1106, EMPIRE BUSINESS HUB, SCIENCE CITY ROAD,AHMEDABAD</b> |

STATEMENT OF ASSETS & LIABILITIES AS AT MARCH 31,2025

|  |  | (Rs. In Lakhs)         |                        |
|--|--|------------------------|------------------------|
| Particulars  |  | As at March<br>31,2025 | As at March<br>31,2024 |
|  |  | AUDITED                | AUDITED                |
| <b>I. EQUITY AND LIABILITIES</b>                                       |  |                        |                        |
| <b>1 Shareholders Funds</b>  |  |                        |                        |
| (a) Share Capital  |  | 2,490.00               | 1,360.00               |
| (b) Reserves and Surplus   |  | 1,963.60               | 1,163.78               |
| (c) Money Received Against Share Warrants                              |  | -                      | -                      |
| <b>Total Shareholders Funds</b>  |  | <b>4,453.60</b>        | <b>2,523.78</b>        |
| <b>3 Non-Current Liabilities</b>                                       |  |                        |                        |
| (a) Long-Term Borrowings   |  | -                      | -                      |
| (b) Deferred Tax Liabilities (Net)                                     |  | -                      | -                      |
| (c) Other Long Term Liabilities  |  | -                      | -                      |
| (d) Long-Term Provisions   |  | -                      | -                      |
| <b>Total Non Current Liabilities</b>                                   |  | <b>-</b>               | <b>-</b>               |
| <b>4 Current Liabilities</b>   |  |                        |                        |
| (a) Short-Term Borrowings  |  | -                      | 423.82                 |
| (b) Trade Payables   |  |                        |                        |
| i) Total Outstanding dues of micro enterprise and small                |  | -                      | 114.88                 |
| ii) Total Outstanding dues of creditors other than micro               |  | 349.66                 | 213.45                 |
| (c) Other Current Liabilities  |  | 124.93                 | 328.81                 |
| (d) Short-Term Provisions  |  | 72.75                  | 81.36                  |
| <b>Total Current Liabilities</b>                                       |  | <b>547.34</b>          | <b>1,162.32</b>        |
| <b>TOTAL &gt; &gt; &gt; &gt;</b>                                       |  | <b>5,000.94</b>        | <b>3,686.10</b>        |
| <b>II. ASSETS</b>  |  |                        |                        |
| <b>Non-Current Assets</b>  |  |                        |                        |
| <b>1</b>   |  |                        |                        |
| (a) Fixed Assets   |  |                        |                        |
| (i) Tangible Assets  |  | 22.31                  | 1.40                   |
| (ii) Intangible Assets   |  | -                      | -                      |
| (iii) Capital Work-In-Progress   |  | -                      | -                      |
| (iv) Intangible Assets under Development                               |  | -                      | -                      |
| (b) Non-Current Investments  |  | -                      | -                      |
| (c) Deferred Tax Assets (Net)  |  | -                      | -                      |
| (d) Long-Term Loans and Advances                                       |  | -                      | -                      |
| (e) Other Non-Current Assets   |  | -                      | -                      |
| <b>Total Non Current Assets</b>  |  | <b>22.31</b>           | <b>1.40</b>            |
| <b>2 Current Assets</b>  |  |                        |                        |
| (a) Current Investments  |  | -                      | -                      |
| (b) Inventories  |  | 221.90                 | 312.50                 |
| (c) Trade Receivables  |  | 861.67                 | 174.26                 |
| (d) Cash and Cash Equivalents  |  | 21.41                  | 12.34                  |
| (e) Short-Term Loans and Advances                                      |  | 2,791.11               | 3,153.49               |
| (f) Other Current Assets   |  | 1,082.54               | 32.11                  |
| <b>Total Current Assets</b>  |  | <b>4,978.63</b>        | <b>3,684.70</b>        |
| <b>TOTAL &gt; &gt; &gt; &gt;</b>                                       |  | <b>5,000.94</b>        | <b>3,686.10</b>        |
| <b>See accompanying notes forming part of the Financial Statements</b> |  |                        |                        |

For, Evoq Remedies Limited

PLACE:AHMEDABAD  
DATE: 10/04/2025

BHUMISHTH PATEL  
Managing Director  
DIN -02516641

| EVOQ REMEDIES LIMITED                                    |
|--|
| CIN:L24230GJ2010PLC059692                                |
| A-1106, EMPIRE BUSINESS HUB, SCIENCE CITY ROAD,AHMEDABAD |

**STATEMENT OF FINANCIALS RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31,2025**

(Rs. In Lakhs)

| Particulars  | Half Year Ended |                   |               | Year Ended      |               |
|--|-----------------|-------------------|---------------|-----------------|---------------|
|  | March 31,2025   | Septmeber 30,2024 | March 31,2024 | March 31,2025   | March 31,2024 |
|  | AUDITED         | UNAUDITED         | AUDITED       | AUDITED         | AUDITED       |
| I. Revenue from Operations   | 1,175.67        | -                 | 14.99         | 1,175.67        | 405.25        |
| II Other Income  | 240.40          | 1.06              | 225.65        | 241.46          | 225.65        |
| <b>Total Revenue (I + II)</b>  | <b>1,416.07</b> | <b>1.06</b>       | <b>240.64</b> | <b>1,417.13</b> | <b>630.90</b> |
| III. Expenses:   |                 |                   |               |                 |               |
| Purchases of material  | 1,217.55        | -                 | 82.41         | 1,217.55        | 265.02        |
| Changes in Inventories   | (65.65)         | 156.25            | (156.59)      | 90.60           | (109.29)      |
| Employee Benefits Expenses   | 5.19            | 1.63              | 1.88          | 6.82            | 7.75          |
| Finance Costs  | -               | -                 | -             | -               | -             |
| Depreciation and Amortization expense                                  | 4.49            | 0.40              | 0.28          | 4.89            | 0.73          |
| Other Expenses   | 79.23           | 5.22              | 258.45        | 84.45           | 405.55        |
| <b>Total Expenses</b>  | <b>1,240.81</b> | <b>163.50</b>     | <b>186.43</b> | <b>1,404.31</b> | <b>569.76</b> |
| IV. Profit before exceptional and extraordinary items and tax (III-IV) | 175.26          | (162.44)          | 54.21         | 12.82           | 61.14         |
| V. Exceptional Items   | -               | -                 | -             | -               | -             |
| Prior Period Expenses  | -               | -                 | -             | -               | -             |
| VI. Profit Before Extraordinary Items and Tax (V - VI)                 | 175.26          | (162.44)          | 54.21         | 12.82           | 61.14         |
| VIII. Extraordinary Items  | -               | -                 | -             | -               | -             |
| IX. Profit before tax (VII- VIII)                                      | 175.26          | (162.44)          | 54.21         | 12.82           | 61.14         |
| X Tax expense:   |                 |                   |               |                 |               |
| (1) Current tax  | 4.00            | -                 | 15.90         | 4.00            | 15.90         |
| (2) Deferred tax   | -               | -                 | -             | -               | -             |
| XI Profit (Loss) for the period from continuing operations (VII-VIII)  | 171.26          | (162.44)          | 38.31         | 8.82            | 45.24         |
| XII Profit/(loss) from discontinuing operations                        | -               | -                 | -             | -               | -             |
| XIII Tax expense of discontinuing operations                           | -               | -                 | -             | -               | -             |
| XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII) | -               | -                 | -             | -               | -             |
| XV Profit (Loss) for the period (XI + XIV)                             | 171.26          | (162.44)          | 38.31         | 8.82            | 45.24         |
| XVI BALANCE BROUGHT FROM PREVIOUS YEAR                                 | -               | -                 | -             | -               | -             |
| XVII BALANCE CARRIED TO BALANCE SHEET                                  | 171.26          | (162.44)          | 38.31         | 8.82            | 45.24         |
| XVIII Details of equity Share Capital                                  |                 |                   |               |                 |               |
| Paid Up Equity Share Capital   | 2,490.00        | 2,490.00          | 1,360.00      | 2,490.00        | 1,360.00      |
| Face Value of equity share Capital                                     | 10.00           | 10.00             | 10.00         | 10.00           | 10.00         |
| XVIII Earnings per equity share:                                       |                 |                   |               |                 |               |
| (1) Basic  | 0.69            | (0.65)            | 0.28          | 0.04            | 0.33          |
| (2) Diluted  | 0.69            | (0.65)            | 0.28          | 0.04            | 0.33          |

Notes :

- The above audited results which are published in accordance with Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ("the Listing Regulations") have been approved by the Board of Directors as their respective meeting held on 10 April, 2025 the financial results have been prepared in accordance with the Accounting Standards (AS) as prescribed under section 133 of the companies Act,2013 read with rule 7of companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof. The above financial results have been reviewed by Audit Committee.
- As per Ministry of Corporate Affairs Notification dated February 16,2015 Companies whose securities listed on SME Exchange as refereed to in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations,2009 are exempted from the compulsory requirement of adoption of IND AS.
- There was 0 investor complaints received/pending as on March 31, 2025
- Previous year/s' period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.
- These result will be filed with BSE Limited.
- Other Current assets includes advances paid to supplier Rs. 1,064.88 Lakhs as on 31st March 2025.
- The Company has only one reportable business segment Le Trading of Agro Commodity. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.

PLACE:AHMEDABAD  
DATE: 10/04/2025

BHUMISHTH PATEL  
Managing Director  
DIN -02516641

|   |
|---|
| <b>EVOQ REMEDIES LIMITED</b>                                    |
| <b>CIN:L24230GJ2010PLC059692</b>                                |
| <b>A-1106, EMPIRE BUSINESS HUB, SCIENCE CITY ROAD,AHMEDABAD</b> |

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2025**

(Rs. In Lakhs)

|  | <b>Year Ended 31st March<br/>2025</b> | <b>Year Ended 31st<br/>March,2024</b> |
|--|---------------------------------------|---------------------------------------|
| <b>Cash flows from operating activities</b>                |                                       |                                       |
| Profit before taxation                                     | 12.82                                 | 61.14                                 |
| <b>Adjustments for:</b>                                    |                                       |                                       |
| Depreciation   | 4.89                                  | 0.73                                  |
| Investment income  | -                                     | -                                     |
| Deferred tax Liability                                     | -                                     | -                                     |
| Interest expense   | -                                     | -                                     |
| Profit / (Loss) on the sale of property, plant & equipment | -                                     | -                                     |
| <b>Working capital changes:</b>                            |                                       |                                       |
| (Increase) / Decrease in trade and other receivables       | (687.41)                              | 1,547.29                              |
| (Increase) / Decrease in inventories                       | 90.60                                 | (109.29)                              |
| (Increase) / Decrease in Short Term Loan & Advance         | 362.38                                | (2,366.57)                            |
| (Increase) / Decrease in Other Current Assets              | (1,050.43)                            | 720.74                                |
| Increase / (Decrease) in Trade payables                    | 21.34                                 | 381.99                                |
| Increase / (Decrease) in Short term Provisions             | (8.61)                                | 3.71                                  |
| Increase / (Decrease) in Other Current Liabilities         | (203.88)                              | 308.14                                |
| Cash generated from operations                             | (1,458.30)                            | 547.88                                |
| Interest paid  | -                                     | -                                     |
| Income taxes paid  | (4.00)                                | (15.90)                               |
| Dividends paid   | -                                     | -                                     |
| <b>Net cash from operating activities</b>                  | <b>(1,462.30)</b>                     | <b>531.98</b>                         |
| <b>Cash flows from investing activities</b>                |                                       |                                       |
| Business acquisitions, net of cash acquired                | -                                     | -                                     |
| Purchase of property, plant and equipment                  | (25.81)                               | (1.20)                                |
| Proceeds from sale of equipment                            | -                                     | -                                     |
| Acquisition of portfolio investments                       | -                                     | -                                     |
| Investment income  | -                                     | -                                     |
| <b>Net cash used in investing activities</b>               | <b>(25.81)</b>                        | <b>(1.20)</b>                         |
| <b>Cash flows from financing activities</b>                |                                       |                                       |
| Proceeds from issue of share capital                       | -                                     | -                                     |
| Proceeds from long-term borrowings                         | -                                     | -                                     |
| Proceeds from Short-term borrowings                        | (423.82)                              | (533.80)                              |
| Payment of Share Application Money                         | -                                     | -                                     |
| Share Capital Issue With Security Premium                  | 1,921.00                              | -                                     |
| <b>Net cash used in financing activities</b>               | <b>1,497.18</b>                       | <b>(533.80)</b>                       |
| <b>Net increase in cash and cash equivalents</b>           | <b>9.07</b>                           | <b>(3.02)</b>                         |
| <b>Cash and cash equivalents at beginning of period</b>    | <b>12.34</b>                          | <b>15.36</b>                          |
| <b>Cash and cash equivalents at end of period</b>          | <b>21.41</b>                          | <b>12.34</b>                          |

For, Evoq Remedies Limited

**BHUMISHTH PATEL**  
Managing Director  
DIN -02516641

PLACE:AHMEDABAD  
DATE: 10/04/2025

Independent Auditor's Report (unmodified opinion) on Audited Half Yearly Financial Results and year to date of the EVOQ REMEDIES LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board Of Directors Of  
EVOQ REMEDIES LIMITED (CIN : L24230GJ2010PLC059692)

Report on the audit of Financial Results

**Opinion**

We have audited the accompanying half yearly Financial Results of EVOQ REMEDIES LIMITED ("the Company"), for the half year ended March 31, 2025 and year to date results for the period from April 1, 2024 to March 31, 2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and the best of our information and according to the explanations given to us these financial results:

- a) Are presented in accordance with requirements of regulation 33 of the listing regulations in this regard; and
- b) Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other financial information for the half year ended March 31, 2025 as well as the year to date results for the period from April 1, 2024 to March 31, 2025 subject to
  - non-payment of previous year income tax dues of ₹67.99 Lacs and previous TDS dues of ₹36.33 Lacs.
  - Debtors outstanding from the opening balance amount to ₹75.26 lakhs, primarily comprising related party transactions. These amounts have been outstanding for a significant period.
  - The Company has reported short-term loans totaling ₹2,791.10 lakhs under 'current Loans,' out of which loan totaling ₹2,506.13 lakhs given to nine related parties. However, the Company has not adhered to the provisions of Sections 177, 185, 188, and 189 of the Companies Act, 2013. Additionally, a sum of ₹505.91 lakhs was provided to 5 related parties, sourced from the Preferential Issue proceeds in FY 2024-25.

**Basis of opinion**

We conducted our audit in accordance with the Standards on Auditing (SA's) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are Independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



### **Management's Responsibilities for the Financial Results**

These half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India including Accounting Standard prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Based on our audit, nothing has come to our attention except the matters described in "Annexure – 1" separately annexed to this report which needs attention, that causes us to believe that the accompanying Financial Results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

we communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For H Thakkar & Co. LLP  
Chartered Accountants  
Firm Registration No. W100891



Hardik Thakkar  
Partner  
Membership No. 146761  
UDIN: 25146761BMONS8831  
Place : Mumbai  
Date : April 10, 2025



**Annexure – 1 to the financial results for the half year ended on March 31, 2025.**

(Pursuant to the regulation 33 of the SEBI (Listing obligation and disclosure requirement) regulations) 2015 to the board of directors of **EVOQ REMEDIES LIMITED.**

1. The Company has received a summons from the Securities and Exchange Board of India (SEBI), dated July 26, 2024, requiring the production of documents for an investigation. SEBI's investigation relates to concerns that the Company's financial statements may have been prepared in a manner detrimental to investors and the integrity of the security market. The Company is in process of providing response to the summons by providing all requested documents and information to SEBI.

Furthermore, on November 25, 2024, SEBI issued a Show Cause letter to the Company regarding the utilization of ₹19.21 crore raised through a preferential allotment. The Company has responded to SEBI, asserting that the funds were utilized for their intended purpose.

We are unable to determine the financial impact of the show cause notice and the transactions referred to therein on the Company's financial position. Consequently, we are unable to comment on whether the financial position of the Company presents a true and fair view.

2. The Company has failed to comply with the mandatory requirements of Section 128(5) of the Companies Act, 2013, and the Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014. Specifically, the Company has not implemented accounting software capable of maintaining a non-disable audit trail, including a comprehensive edit log with date and time stamps for all modifications to the books of account. Consequently, we are unable to assess the reliability and accuracy of the audit trail.
3. Advances amounting to ₹1,064.88 lakhs given to suppliers are subject to confirmation. Hence, we are unable to determine whether any adjustments are necessary and their potential impact on the financial statements.
4. The Company has received an order from the Goods and Services Tax (GST) department dated February 2, 2025, pertaining to the financial year 2017-18, for ₹655.03 lakhs. Given that this matter is currently subject to litigation, we are unable to assess the necessity of any potential adjustments to the financial statements.
5. As of the financial year 2023-24, the Company's books of accounts reflect an outstanding income tax provision of ₹67.99 lakhs.

Furthermore, according to the Income Tax Department's records, there is a disputed income tax demand of ₹139.99 lakhs, along with associated interest of ₹28.35 lakhs, which are currently unpaid and not recorded in the Company's accounts. Given that these matters are under litigation, we are unable to assess whether any adjustments to recorded or unrecorded liabilities or the financial results are necessary.


6. Debtors outstanding from the opening balance amount to ₹75.26 lakhs, primarily comprising related party transactions. These amounts have been outstanding for a significant period. The Company is in the process of reconciliation and obtaining confirmations; however, these have not been received as of the reporting date. Consequently, we are unable to quantify the financial impact, if any, on the Company's financial position.
7. The Company has deducted/collected TDS and TCS amounting to ₹36.71 lakhs, however, the amounts remain unpaid to the government and have been outstanding since the opening balance, including the current year. Consequently, we are unable to determine whether any adjustments are necessary concerning the recorded liability and its potential impact on the financial statements.





8. For the financial year ended March 31, 2025, the company has failed to appoint an internal auditor as mandated by Section 138 of the Companies Act, 2013. Consequently, no internal audit activities have been conducted. This non-compliance exposes the company to increased risks, including potential financial irregularities, operational inefficiencies, and regulatory penalties.
9. The Company has reported short-term loans totaling ₹2,791.10 lakhs under 'current Loans,' out of which loan totaling ₹2,506.13 lakhs given to nine related parties. However, the Company has not adhered to the provisions of Sections 177, 185, 188, and 189 of the Companies Act, 2013. Additionally, a sum of ₹505.91 lakhs was provided to 5 related parties, sourced from the Preferential Issue proceeds for FY 2024-25.

For H Thakkar & Co. LLP  
Chartered Accountants  
Firm Registration No. W100891

  
Hardik Thakkar  
Partner  
Membership No. 146761  
UDIN: 25146761BMONSN8831  
Place : Mumbai  
Date : April 10, 2025

# Evoq Remedies Limited

CIN: L24230GJ2010PLC059692

**Regd. Office:** A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road,  
Sola Ahmedabad, Gujarat, India – 380060

**E-mail:** [evoqremedies@gmail.com](mailto:evoqremedies@gmail.com) **Website:** [www.evoqremedies.com](http://www.evoqremedies.com)

---

**Date:** 10<sup>th</sup> April, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400 001.

Dear Sir / Madam,

**Sub: Declaration in respect of Unmodified Opinion on Audited Financial Result for  
the Quarter and Financial Year ended on 31<sup>st</sup> March, 2025**

**Ref: Security Id: EVOQ / Code: 543500**

We hereby declared that the Statutory Auditor of the Company, M/s. H Thakkar & Co. LLP, has issued Audit Report with Unmodified Opinion on Audited Financial Result for the Half Year and Financial Year ended as on 31<sup>st</sup> March, 2025.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25<sup>th</sup> May, 2016.

Kindly take the same on your record and oblige us.

Thanking You.

**For, Evoq Remedies Limited**

**Bhumishth Patel**  
**Managing Director**  
**DIN: 02516641**